T Cell Based Immunotherapy: A Deeper Dive III
This conference brought together some of the most talented scientists involved with understanding T cell function and promoted discussions for therapeutic intervention in the setting of tumor immunology.
We hope you will join us for the next one in 2022!
Thank you to our sponsors, to the Fairmont Kea Lani and to the fantastic speakers!
Robert Schreiber, Washington University School of Medicine in St. Louis
”High Dimensional Profiles of Successful vs Unsuccessful Cancer Immunotherapy”
James Allison, MD Anderson
”Immune Checkpoint Blockade in Cancer Therapy: New insights, opportunities, and prospects for cures”
Dario Vignali, University of Pittsburgh
”Inhibitory Mechanisms in the Tumor Microenvironment”
Anthony Vella, UCONN Health
"Examining power of dual costimulation through CD134 and CD137 in T cells"
Bernard Fox, Earle A. Chiles Research Institute, Providence Cancer Institute
"Evolving Concepts of Anticancer Immunity that May Help to #FinishCancer"
Carl Ware, Sanford Burnham Prebys Medical Discovery Institute
"Impact of the HVEM Network in Controlling Immune Function"
Andrew Weinberg, Earle A. Chiles Research Institute, Providence Cancer Institute
“Targeting tumor-reactive T cells through anti-OX40 and TGFb receptor blockade”
Stephen Hedrick, UC San Diego
”T Cell Programming for Immunotherapy”
Randy Noelle, Dartmouth
”VISTA: T cell tolerance, TME remodelling and it’s impact on tumor immunity.”
Phil Greenberg, University of Washington
”Engineering T cells to eradicate malignancies”
Erika Pearce, Max Planck Institute of Immunobiology and Epigenetics
Douglas Green, St. Judes Childrens Research Hospital
”LC3-associated phagocytosis and anti-cancer immunity”
Greg Delgoffe, University of Pittsburgh
”Fueling effective cancer immunotherapy through metabolic reprogramming”
John Wherry, University of Pennsylvania
”Molecular Mechanisms of T Cell Exhaustion”
Samir Khlief, Georgetown University
”Overcoming PD1 Resistance”
Jedd Wolchok, Memorial Sloan Kettering Cancer Center
”Exploring Mechanisms for Checkpoint Blockade”
Carl June, University of Pennsylvania
”Designing better CARs”
Padmanee Sharma, MD Anderson
”From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy.”
Robert Ferris, University of Pittsburgh
“Analysis of intratumoral mechanisms of escape and immunotherapeutic resistance using neoadjuvant clinical trials”
Brendan Curti, Earle A. Chiles Research Institute, Providence Cancer Institute
”Neoadjuvant OX40 Co-stimulation & TIL”
James Heath, Institute for Systems Biology
”Molecular view of Cancer Immunotherapy”
Eric Tran, Earle A. Chiles Research Institute, Providence Cancer Institute
”Tumor genome guided adoptive T-cell transfer therapy”
Kelly Paulson, Fred Hutchinson Cancer Research Center
”Mechanistic insights into late cancer escape from T cell immunotherapy as revealed by scRNAseq”